Why Marijuana Legalization Could Give Medicinal Sales a Boost Too

Canopy Growth Corp (TSX:WEED)(NYSE:CGC) has seen medicinal marijuana sales soar in recent years, but there are still opportunities for even more growth ahead.

| More on:

Marijuana legislation was passed earlier this year and recreational pot sales are expected to commence in mid-October, and while medical marijuana has been legalized for some time now, it too could benefit from the new law.

It’s not as if companies are struggling to sell medical marijuana, but legalization will make it easier for patients and those looking for the benefits of cannabidiol to get easier access to cannabis.

Canopy Growth Corp. (TSX:WEED)(NYSE:CGC) and others in the industry have had to rely on medicinal sales so far, and while there has been grown in that segment, there’s clearly much more that could be achieved. In its most recent fiscal year, Canopy Growth recorded $78 million in sales, which is nearly double the $40 million it recorded in the prior year and triple the revenue it booked in 2016.

Sales have been growing at a strong pace — and that’s with medical marijuana still not being covered by most healthcare plans in the country.

What’s holding medical marijuana back?

In a recent interview with the CBC, Dr. Jeff Blackmer of the Canadian Medical Association said that many doctors are still hesitant to prescribe medical marijuana, simply because the benefits remain unclear. A big reason for that is there have been limited studies and testing done on marijuana, which has made it harder to validate its effectiveness in treating patients.

While there are no big obstacles holding back research in Canada, in the U.S., where lots of money is spent on researching various drugs, because marijuana is a Schedule I drug, some big hurdles that prevent cannabis research. Until we see marijuana legalized federally south of the border, the studies we see on cannabis are going to remain limited.

This brings us back to where we are today, and why legalization will open the doors not only for recreational users, but medicinal ones as well. Without relying on a doctor’s prescription, patients can freely seek out cannabis in order to help with their ailments. And although it hasn’t generally been hard to get a prescription for marijuana, legalization will make it even easier to do so, which should enable even more patients to get access to cannabis.

Still many opportunities ahead

Medical marijuana will get a boost from legalization, but without doctors endorsing it or healthcare plans covering it, there will still be patients who remain hesitant to try it without their physician’s recommendation and with the cost not being covered.

Once those hurdles are cleared, we could see even more demand for medical marijuana, and it won’t be until then that its full potential will be realized.

Unfortunately, it could still take many years before we see that happen, and it will be dependent on what studies happen in the future. As countries around the world take steps in legalizing marijuana, we’ll see more data on cannabis come in, but the turning point will be if and when the drug is legalized in the U.S.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any of the stocks mentioned.

More on Investing

rail train
Stocks for Beginners

CP Stock: 1 Key Catalyst Investors Should Watch

After a positive surprise in the last quarter, CP stock (TSX:CP) recently made a change that should have investors excited…

Read more »

Payday ringed on a calendar
Dividend Stocks

Cash Kings: 3 TSX Stocks That Pay Monthly

These stocks are rewarding shareholders with regular monthly dividends and high yields, making them compelling investments for monthly cash.

Read more »

grow dividends
Tech Stocks

Celestica Stock Is up 62% in 2024 Alone, and an Earnings Pop Could Bring Even More

Celestica (TSX:CLS) stock is up an incredible 280% in the last year. But more could be coming when the stock…

Read more »

Airport and plane
Stocks for Beginners

Is Air Canada Stock a Good Buy in April 2024?

Despite rallying by over 20% in the last six months, Air Canada stock could be a great buy for the…

Read more »

Businessman holding AI cloud
Tech Stocks

Stealth AI: 1 Unexpected Stock to Win With Artificial Intelligence

Thomson Reuters (TSX:TRI) stock isn't widely-known for its generative AI prowess, but don't count it out quite yet.

Read more »

Shopping and e-commerce
Tech Stocks

Missed Out on Nvidia? My Best AI Stock to Buy and Hold

Nvidia (NASDAQ:NVDA) stock isn't the only wonderful growth stock to hold for the next 10 years and beyond.

Read more »

Human Hand Placing A Coin On Increasing Coin Stacks In Front Of House
Dividend Stocks

Up 13%, Killam REIT Looks Like It Has More Room to Run

Killam REIT (TSX:KMP.UN) has seen shares climb 13% since market bottom, but come down recently after 2023 earnings.

Read more »

crypto, chart, stocks
Energy Stocks

If You Had Invested $10,000 in Enbridge Stock in 2018, This Is How Much You Would Have Today

Enbridge's big dividend yield isn't free money. Here's why.

Read more »